Trial Profile
An Open Label Extension of the TG1101-RMS201 Trial, for Subjects Currently Enrolled in TG1101-RMS201Treated With Ublituximab for Relapsing Forms of Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2022
Price :
$35
*
At a glance
- Drugs Ublituximab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
- 20 Dec 2022 Status changed from active, no longer recruiting to completed.
- 21 Nov 2022 Planned End Date changed from 30 Nov 2022 to 1 Jun 2023.
- 21 Nov 2022 Planned primary completion date changed from 30 Nov 2022 to 1 Jun 2023.